CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Hamlet BioPharma AB is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Hamlet BioPharma AB
Klinikgatan 32
Phone: +46 40122500p:+46 40122500 LUND, 222 42  Sweden Ticker: HAMLET BHAMLET B
Business Summary
Hamlet BioPharma AB, formerly Hamlet Pharma AB, is a Sweden-based pharmaceutical company that develops new drugs for the treatment and prevention of cancer. The Company provides new therapeutic solutions using a peptide-based molecular approach for targeting and killing tumour cells with greater precision. Its synthetic drug candidate Alpha1H kills tumor cells quickly, both in the laboratory and in animal models and in treated patients, where the response can be measured already within a few hours. The other product BAMLET kills cancer cells and has shown effects against growing tumor tissue, especially for colon cancer. Hamlet Pharma is therefore driving the development of BAMLET as a future drug against cancer. The Company intends to establish production of BAMLET primarily for clinical studies of the treatment/prevention of colon cancer in the gastrointestinal tract and oral cancer in the oral cavity.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20236/30/2023Yes----

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board CatharinaSvanborg
Acting Chief Executive Officer MartinErixon 10/11/2023 4/5/2022
Director BillHansson 3/4/2021 3/4/2021
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Selectimmune Pharma AB Klinikgatan 32 Lund Sweden

Business Names
Business Name
HAMLET
HAMLET B
Selectimmune Pharma AB

General Information
Number of Employees: 7 (As of 12/31/2023)
Outstanding Shares: 238,035,864 (As of 1/19/2024)
Stock Exchange: AKT
Email Address: info@hamletpharma.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024